Reddit Posts
Mentions
How tf did $CGEM go up +36% today and is currently still going up on overnight markets? This has to be a meme stock no way a Biotech company moves like that LOL
Congrats to all CGEM investors you guys really are getting a real squeeze
CGEM is up 27% and it's not on the WSB bulletin board wtf LOL
CGEM, you heard it here first
CGEM and CABA mooning today but CLYM goes \*chirp chrip\* PAIN! The market doesn't think antibodies are enough and will need bispecifics and CAR-Ts :|
Friendship ended with BYND now CGEM is beat frien
#TLDR --- Ticker: CGEM Direction: Up Prognosis: Buy shares and hold for upcoming clinical trial catalysts. Analysts are targeting a 200-300% upside ($26+). Risk Level: Boom or Bust Positions: 32k in shares
📌 Thesis: Why CGEM could be a major move CGEM is a clinical-stage biotech company (Cullinan Therapeutics, Inc.) developing therapies for autoimmune diseases & cancer. The stock is trading at ~$8 (recently around $7.70-8.50) with a 52-week low of ~$5.68 and a high near ~$17.50. Analyst consensus: “Strong Buy” with average 12-month price targets ~$26 or higher — implying +200%-300% upside from current levels. Notable insider/institution activity: For example, one major shareholder increased their position (~150,000 shares) recently at ~$8.86 average Story catalysts: Phase trials (e.g., their lead candidate for NSCLC with EGFR Ex20 insertion mutations) and autoimmune program CLN-978 entering trials. ⚠️ Risks (because biotech = boom or bust) CGEM has no revenue (or negligible) and is currently unprofitable with large losses. StockAnalysis Clinical trial risk = data could disappoint, regulatory risk, competition risk. From analysts: “Bears say competition, regulatory risks, slower-than-expected enrolment” etc. TipRanks High institutional ownership (~86%) means less free float and possibly less retail “meme-moment” volume. If the drug fails, downside could be steep. 🎯 Play-style & target If you believe the trial data is going to be positive and a catalyst is near, you could enter at current levels (~$7.70-8.50) and target $25-$30+ (i.e., ~3x). Keep your risk tight: biotech can whipsaw hard. Consider risk‐management: only allocate what you’re willing to lose. Watch for upcoming binary catalysts/events (trial readouts, regulatory filings) which could send the move. If you want to “set it and forget it” you might hold for 12+ months, but you’ll need the stomach for volatility.
Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912. The purchases occurred between October 14 and October 17, 2025. The transactions come as InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $21 and $34. According to a Form 4 filing with the Securities and Exchange Commission, Lynx1 Capital Management acquired 15,032 shares on October 14 at prices ranging from $7.50 to $7.68, for a total of $114,053. On October 15, the firm bought 51,500 shares at prices between $7.88 and $8.00, worth $408,999. This was followed by the purchase of 150,000 shares on October 16, at prices ranging from $8.68 to $9.22, for a total of $1,328,250. The final transaction on October 17 involved the acquisition of 32,217 shares at prices between $7.78 and $7.85, for a total of $252,610. The company maintains a strong financial position with a current ratio of 9.83 and minimal debt. InvestingPro data reveals 8 additional key financial metrics and insights available for subscribers. Following these transactions, Lynx1 Capital Management LP directly holds 8,797,833 shares of Cullinan Therapeutics, representing a significant portion of the company’s $498.59 million market capitalization. Weston Nichols, as sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912. The purchases occurred between October 14 and October 17, 2025. The transactions come as InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $21 and $34. According to a Form 4 filing with the Securities and Exchange Commission, Lynx1 Capital Management acquired 15,032 shares on October 14 at prices ranging from $7.50 to $7.68, for a total of $114,053. On October 15, the firm bought 51,500 shares at prices between $7.88 and $8.00, worth $408,999. This was followed by the purchase of 150,000 shares on October 16, at prices ranging from $8.68 to $9.22, for a total of $1,328,250. The final transaction on October 17 involved the acquisition of 32,217 shares at prices between $7.78 and $7.85, for a total of $252,610. The company maintains a strong financial position with a current ratio of 9.83 and minimal debt. InvestingPro data reveals 8 additional key financial metrics and insights available for subscribers. Following these transactions, Lynx1 Capital Management LP directly holds 8,797,833 shares of Cullinan Therapeutics, representing a significant portion of the company’s $498.59 million market capitalization. Weston Nichols, as sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912. The purchases occurred between October 14 and October 17, 2025. The transactions come as InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $21 and $34. According to a Form 4 filing with the Securities and Exchange Commission, Lynx1 Capital Management acquired 15,032 shares on October 14 at prices ranging from $7.50 to $7.68, for a total of $114,053. On October 15, the firm bought 51,500 shares at prices between $7.88 and $8.00, worth $408,999. This was followed by the purchase of 150,000 shares on October 16, at prices ranging from $8.68 to $9.22, for a total of $1,328,250. The final transaction on October 17 involved the acquisition of 32,217 shares at prices between $7.78 and $7.85, for a total of $252,610. The company maintains a strong financial position with a current ratio of 9.83 and minimal debt. InvestingPro data reveals 8 additional key financial metrics and insights available for subscribers. Following these transactions, Lynx1 Capital Management LP directly holds 8,797,833 shares of Cullinan Therapeutics, representing a significant portion of the company’s $498.59 million market capitalization. Weston Nichols, as sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
CGEM is my latest one for their earnings. Hoping for a good update on their research etc. they already starting to jump around.
Natgas has reclaimed support after getting oversold, so I'm going to try another bounce trade with BOIL. Got a lot of exposure to bio now so I'm going to skip most of it. But if you are looking for good bio breakout candidates, I've got ACLX, CGEM, PHR, and RDUS on my watchlist. Indices looking very bullish. Good luck everyone.
$CGEM spiking up! ​ DD: Fuck cancer